Reconciling Opportunistic and Population Screening in Clinical Genomics
- PMID: 30611438
- PMCID: PMC6339566
- DOI: 10.1016/j.mayocp.2018.08.028
Reconciling Opportunistic and Population Screening in Clinical Genomics
Abstract
Opportunistic genomic screening is becoming increasingly common as laboratories adopt recommendations to report secondary genomic findings. In parallel, interest in using genome sequencing as a population screening test has grown rapidly. We consider here 3 potential applications of genome sequencing for preventive medicine: (1) provider-ordered predispositional testing in healthy adults, (2) indication-based testing with opportunistic screening of secondary results, and (3) population screening in the public health context. We conclude that despite superficial similarities, there are important and fundamental differences in the way medical risks and benefits can be addressed in these 3 contexts. Recommendations to report secondary genomic findings should not be interpreted as an endorsement of population genomic screening. Ongoing work is developing the evidence that will be needed to fully justify current and future initiatives in population genomic screening. Ongoing work is developing the evidence that will be needed to fully justify current and future initiatives in population genomic screening.
Copyright © 2018 Mayo Foundation for Medical Education and Research. All rights reserved.
Conflict of interest statement
Competing Interests
Dr. Green receives compensation for speaking or consultation from AIA, Helix, Ohana, Prudential and Veritas; and is co-founder, advisor and equity holder in Genome Medical, Inc.
Comment in
-
Genomics as a Scientifically Based Fortune-teller.Mayo Clin Proc. 2019 Jan;94(1):7-9. doi: 10.1016/j.mayocp.2018.11.008. Mayo Clin Proc. 2019. PMID: 30611456 No abstract available.
References
-
- Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med. 2014;370(25):2418–2425. - PubMed
-
- Offit K Decade in review--genomics: a decade of discovery in cancer genomics. Nat Rev Clin Oncol. 2014;11(11):632–634. - PubMed
-
- ACMG Board of Directors. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med. 2015;17(1):68–69. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources